MACK — Merrimack Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $223.75m
- -$20.36m
- 42
- 37
- 78
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.01 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.02% | ||
| Return on Equity | -1.12% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Directors
- Gary Crocker CHM (69)
- Eric Andersen IND (43)
- Noah Levy IND (43)
- Ulrik Nielsen IND (49)
- Russell Ray IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 6th, 2010
- Public Since
- March 29th, 2012
- No. of Shareholders
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 14,788,369
- Address
- One Broadway, 14Th Floor, CAMBRIDGE, 02142
- Web
- https://www.merrimack.com/
- Phone
- +1 6174411000
- Contact
- Tim Surgenor
- Auditors
- Marcum LLP
Upcoming Events for MACK
Q2 2024 Merrimack Pharmaceuticals Inc Earnings Release
Q3 2024 Merrimack Pharmaceuticals Inc Earnings Release
Similar to MACK
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Merrimack Pharmaceuticals share price?
As of Today at 22:01 UTC, shares in Merrimack Pharmaceuticals are trading at $15.13. This share price information is delayed by 15 minutes.
How has the Merrimack Pharmaceuticals share price performed this year?
Shares in Merrimack Pharmaceuticals last closed at $15.13 and the price had moved by +18.48% over the past 365 days. In terms of relative price strength the Merrimack Pharmaceuticals share price has underperformed the S&P500 Index by -6.07% over the past year.
What are the analyst and broker recommendations for Merrimack Pharmaceuticals?
The overall consensus recommendation for Merrimack Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Merrimack Pharmaceuticals dividend yield?
Merrimack Pharmaceuticals does not currently pay a dividend.
Does Merrimack Pharmaceuticals pay a dividend?
Merrimack Pharmaceuticals does not currently pay a dividend.
When does Merrimack Pharmaceuticals next pay dividends?
Merrimack Pharmaceuticals does not currently pay a dividend.
How do I buy Merrimack Pharmaceuticals shares?
To buy shares in Merrimack Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Merrimack Pharmaceuticals?
As of the previous close price of $15.13, shares in Merrimack Pharmaceuticals had a market capitalisation of $223.75m.
Where are Merrimack Pharmaceuticals shares listed?
Here are the trading details for Merrimack Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MACK
What kind of share is Merrimack Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Merrimack Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Merrimack Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Merrimack Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Merrimack Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +1.24%.
As of the last closing price of $15.13, shares in Merrimack Pharmaceuticals were trading +13.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Merrimack Pharmaceuticals PE Ratio?
The Merrimack Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' management team is headed by:
- Gary Crocker - CHM
- Eric Andersen - IND
- Noah Levy - IND
- Ulrik Nielsen - IND
- Russell Ray - IND